Sort by 
Page
Showing 1 - 25 of 286 documents.
Clinical cardiology
5 COMMENTS - Dec 2, 2008 16:00 EST
Twenty years of research show that generic CVD drugs across nine classes are just as good as brand-name agents, yet editorials often boost superiority of brand-name agents. (Kesselheim AS et al. JAMA 2008; 300:2514-2526.)
Lipid/Metabolic
Dec 2, 2008 13:30 EST
It's not just the amount of alcohol is drunk, but the way that it is drunk that is important when it comes to cardiovascular health. New research suggests a precise mechanism by which binge drinking might contribute to atherosclerosis. (Redmond EM et al. Atherosclerosis; published online before print October 18, 2008.)
Hypertension
Nov 27, 2008 17:00 EST
Two new studies published online this week help shed light on the off-target toxicity of the CETP inhibitor torcetrapib, but the studies conflict regarding the atheroprotective functionality of the HDL cholesterol resulting with the drug. (Vergeer M et al. Nicholls SJ et al. Circulation; published online before print November 25, 2008.)
Lipid/Metabolic
Nov 25, 2008 17:00 EST
New research has found that type 2 diabetics who carry two copies of the variant 9p21 allele are at higher risk of coronary artery disease and that this risk is amplified if they also have poor glycemic control. The findings may have prognostic implications for such patients, say the researchers. (Doria A et al. JAMA 2008; 300:2389-2397.)
Heart failure
14 COMMENTS - Nov 24, 2008 18:00 EST
A retrospective analysis of Medicare beneficiaries found all-cause mortality to be increased by 15% in patients taking rosiglitazone, while congestive heart failure hospitalizations were 13% higher. Stroke and MI, however, were no different between the treatment groups. (Winkelmayer WC et al. Arch Intern Med 2008; 168:2368-2375.)
Acute Coronary Syndrome
1 COMMENT - Nov 24, 2008 13:30 EST
UPDATED WITH COMMENTARY // A new anti-inflammatory compound, VIA-2291, has shown promise in a phase 2 trial in patients with acute coronary syndrome. The results provide sufficient basis to move forward with additional studies of the drug, says the lead investigator, but another expert disagrees. (American Heart Association 2008 Scientific Sessions.)
Clinical cardiology
1 COMMENT - Nov 14, 2008 09:15 EST
Listening to enjoyable music may be good for cardiovascular health in the same way that laughter is beneficial, new research suggests. (American Heart Association 2008 Scientific Sessions.)
Lipid/Metabolic
19 COMMENTS - Nov 13, 2008 15:00 EST
The thiazolidinedione, given for 18 months, didn't appear to reverse or slow disease progression compared with the same duration of treatment with a sulfonylurea, according to the IVUS-based study. Investigators point to hints that that rosiglitazone may have slowed atherosclerosis in such patients with longer-established diabetes. (American Heart Association 2008 Scientific Sessions.)
Prevention
Nov 12, 2008 15:00 EST
A new study in which the family members of patients hospitalized for cardiovascular disease were given CVD risk screening and lifestyle advice has shown that it is useful to take advantage of such "motivational moments." But the results could be improved upon, illustrating that it is difficult to change behavior in the "toxic environment" of the US, said the discussant. She stressed that better interventions—such as adopting the Mediterranean diet—are urgently needed. (Mosca L et al. Circ Cardiovasc Qual Outcomes; published online before print November 12, 2008. American Heart Association 2008 Scientific Sessions.)
Lipid/Metabolic
1 COMMENT - Nov 12, 2008 09:00 EST
A new observational study finds an association between higher levels of nonfasting triglycerides and increasing risk for ischemic stroke. (Freiberg JJ et al. JAMA 2008; 300:2142-2152. American Heart Association 2008 Scientific Sessions.)
Hypertension
7 COMMENTS - Nov 11, 2008 13:30 EST
Results of a small randomized trial show that hibiscus tea given three times daily reduced systolic blood pressure by about 7 mm Hg in prehypertensive and mildly hypertensive subjects. (American Heart Association 2008 Scientific Sessions.)
Interventional/Surgery
2 COMMENTS - Nov 10, 2008 15:45 EST
The results highlight the preserved efficacy of drug-eluting stents observed in other randomized trials and also point to no increased safety concerns in long-term follow-up. Investigators say drug-eluting stents should be favored over bare-metal stents on a patient-by-patient basis, with their ability to take dual antiplatelet therapy the primary caveat. (Garg P et al. Circulation; published online before print November 10, 2008. American Heart Association 2008 Scientific Sessions.)
Lipid/Metabolic
11 COMMENTS - Nov 9, 2008 21:30 EST
Low-dose aspirin didn't cut the risk of cardiovascular events but may have reduced CV mortality, a secondary end point, in the randomized but open-label trial conducted in Japan; clinical events were unexpectedly few, compromising the study's statistical power. (Ogawa H et al. JAMA 2008; 300:2180-2181. American Heart Association 2008 Scientific Sessions.)
Lipid/Metabolic
Nov 9, 2008 20:30 EST
The SEARCH trial showed no effect on major vascular events with either an intensive 80-mg dose of simvastatin compared with a 20-mg dose or with homocysteine lowering using folic acid and vitamin B12. But the statin data fit with other trials in the field, showing a "clear picture" emerging when it comes to the more-vs-less data on statins, say the UK investigators. (American Heart Association 2008 Scientific Sessions.)
Clinical cardiology
35 COMMENTS - Nov 9, 2008 19:30 EST
Some back-of-the-envelope analyses suggest that the public-health implications of using statins in primary prevention, especially among individuals considered "healthy" by conventional definitions, is weighing heavily on the minds of some cardiologists. heartwire spoke with many experts to get their take on the new JUPITER data. (American Heart Association 2008 Scientific Sessions.)
Clinical cardiology
72 COMMENTS - Nov 9, 2008 09:00 EST
There are a number of adjectives being thrown at the JUPITER study—groundbreaking and paradigm shifting are just two—but many experts believe the study, which showed significant cardiovascular risk reduction among healthy individuals with elevated CRP levels, is likely going to shake up the field of primary prevention. (Ridker PM et al. New Engl J Med; published online before print November 9, 2008. American Heart Association 2008 Scientific Sessions.)
Prevention
Nov 6, 2008 18:30 EST
Focusing on the classic risk factors for coronary heart disease and ensuring that best-practice interventions to reduce absolute risk are implemented across the board could largely eliminate socioeconomic differences in CHD deaths, a new British study predicts (Kivimäki M et al. Lancet 2008; 372:1648-1654.)
Clinical cardiology
Nov 5, 2008 17:30 EST
The company announced its decision after regulatory agencies asked for a discontinuation of the company's clinical trials.
Lipid/Metabolic
1 COMMENT - Nov 5, 2008 12:45 EST
A new study has shown mixed results with regard to the effects of hormone-replacement therapy on lipids in women around the time of menopause and also shows that HRT unfavorably affects inflammatory markers. The results muddy the waters somewhat for the so-called "time window" for the use of HRT, say the researchers. (Sowers MR et al. Arch Int Med 2008; 168:2146-2153.)
Lipid/Metabolic
7 COMMENTS - Nov 4, 2008 16:45 EST
Full results from the JUPITER trial will be released during the opening late-breaking clinical-trials session at the American Heart Association 2008 Scientific Sessions.
Prevention
9 COMMENTS - Nov 3, 2008 17:00 EST
The data do not support statin use in primary prevention of cardiovascular events for women, and any advertising claims made by drugmakers are vulnerable to legal action, according to one legal expert. Cardiologists, however, argue that the absence of information doesn't mean the drugs don't work in women, and they continue to prescribe them. (Eisenberg T et al. J Empir Leg Stud 2008; 5:507-550.)
Lipid/Metabolic
Oct 29, 2008 17:00 EDT
Genetically elevated CRP levels were associated with but probably didn't influence cardiovascular and cerebrovascular risk in a huge combined analysis of four Danish cohort studies, researchers say. (Zacho J et al. N Engl J Med 2008; 359:1897-1908.)
Lipid/Metabolic
Oct 27, 2008 16:00 EDT
Of all such agents used in 40 select clinical trials, only metformin significantly reduced cardiovascular mortality. An accompanying editorial highlights limitations of meta-analyses and the shortfalls in knowledge about the CV effects of these agents. (Selvin E et al. Arch Intern Med 2008; 168:2070-2080.)
Lipid/Metabolic
9 COMMENTS - Oct 27, 2008 16:00 EDT
The decreased mortality rates among those pretreated with statin therapy became evident during the first weeks of hospitalization for pneumonia and persisted to at least 90 days, report investigators. (Thomsen R et al. Arch Intern Med 2008; 168:2081-2087.)
Brain/Kidney/Peripheral
Oct 24, 2008 18:00 EDT
New data from 18 European countries on the fully percutaneous aortic valve speak to low 30-day mortality and improved valve function sustained over the longer term. So why the holdup in the US, where nary a feasibility study has been conducted? (TCT 2008.)

Sort by 
Page
Showing 1 - 25 of 286 documents.
button
Previews
Featured programs
Poll
Following JUPITER, I am going to screen for hsCRP (or recommend screening to my referral base) to risk stratify:

All patients
Statin-naïve patients
Those with normal lipids & 1 other risk factor
Intermediate risk patients

Inside: Lipid/Metabolic
Lipid/Metabolic
1 COMMENT - Nov 10, 2008 10:55 EST
How can we better identify patients at risk of developing cardiovascular disease? Drs Davidson, Ginsberg, and Chapman provide the lowdown on strategies to identify and treat patients with mixed dyslipidemia and ensure they achieve all their target lipid levels.
Lipid/Metabolic
3 COMMENTS - Jul 14, 2008 09:28 EDT
When and how do you treat elevated triglycerides? Click to take the survey and immediately compare your answers with your colleagues. Your responses will guide us in our selection of topics for future CME programming.
Lipid/Metabolic
Sep 8, 2008 10:00 EDT
Navigating the SEAS: Join Drs Fitchett and Chan as they present their views on the latest controversial findings from clinical on treating aortic stenosis with statins alone or in combination with ezetimibe.